Corpus Intelligence IC Memo — ST. MARYS HEALTHCARE 2026-04-26 14:30 UTC
IC Memo — ST. MARYS HEALTHCARE
Investment Committee Memorandum | NY | 100 beds | Grade C | EBITDA uplift $11.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. MARYS HEALTHCARE

CCN 330047 | MONTGOMERY, NY | 100 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST. MARYS HEALTHCARE is a 100-bed under-performing / distressed in MONTGOMERY, NY with $151.8M in net patient revenue and a -21.9% operating margin. The hospital serves a payer mix of 23.6% Medicare, 2.7% Medicaid, and 73.7% commercial.

Thesis: Turnaround. Our ML models identify $11.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -21.9% to -14.5% (+736bps).

Net Revenue HCRIS$151.8M
Current EBITDA COMPUTED$-33.2M
Operating Margin COMPUTED-21.9%
Occupancy HCRIS47.7%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS28.8%
Distress Probability ML47.5%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
74
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -21.9% places it below the state median. Among 74 size-comparable peers (50-200 beds), the median margin is -14.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (50-200), prioritizing same-state peers. 74 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. MARYS HEALTHCARE (Target)NY100$151.8M-21.9%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
QUEENS HOSPITAL CENTERNY200$637.2M4.9%
MARY IMOGENE BASSETT HOSPITALNY160$529.1M-31.6%
SARATOGA HOSPITALNY171$431.9M-12.3%
NORTHERN WESTCHESTER HOSPITALNY162$416.0M-4.5%
OUR LADY OF LOURDES MEMORIAL HNY175$411.8M-24.9%
MATHER HOSPITALNY195$387.3M-3.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $11.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.2M+210bp18mo
Cost to Collect4.5%2.5%$3.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.8M+122bp9mo
Clean Claim Rate88.0%96.0%$97K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.2M
Cost to Collect
$3.0M
Denial Rate Reduction
$3.0M
A/R Days Reduction
$1.8M
Clean Claim Rate
$97K
Total EBITDA Uplift$11.2M
Current EBITDA$-33.2M
+ RCM Uplift+$11.2M
Pro Forma EBITDA$-22.1M
Current Margin-21.9%
Pro Forma Margin-14.5%
WC Released (1x)$5.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-51.1M$-107.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-51.1M$-134.9M0.00x-100.0%
Bull Case9.0x11.0x$-46.0M$-114.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-46.0M$-138.6M0.00x-100.0%
Bear Case11.0x10.0x$-56.2M$-146.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-56.2M$-179.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 74 hospitals with 50-200 beds
  • Same-state prioritization (n=75)
  • Comp margins: P25=-29.3% / P50=-14.2% / P75=-8.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.